Correlation of Peripheral-Blood Gene Expression With the Extent of Coronary Artery Stenosis

Abstract

Background-The molecular pathophysiology of coronary artery disease (CAD) includes cytokine release and a localized inflammatory response within the vessel wall. The extent to which CAD and its severity is reflected by gene expression in circulating cells is unknown. Key Words: gene expression Ⅲ coronary disease Ⅲ blood, peripheral Ⅲ atherosclerosis Ⅲ leukocytes Ⅲ polymerase chain reaction Ⅲ stenosis C oronary artery disease (CAD) and sequelae of atherosclerotic disease such as stroke and myocardial infarction are the largest source of morbidity and mortality in the developed world. The risk of developing CAD events over time can be estimated with clinical factors and family history, as in the Framingham Risk Score. 1 For patients with suspicious clinical histories, extant coronary disease may be diagnosed by indirect methods, including nuclear perfusion imaging and computed tomography angiography, but coronary angiography remains the "gold standard." These tests have drawbacks, including radiation exposure, contrast agent allergy, nephrotoxicity, and, in the case of coronary angiography, invasiveness of the procedure. Therefore, the development of a blood test that reliably identified patients with CAD would have diagnostic utility. Methods and Results-From Editorial see p 7 Clinical Perspective see p 38The cellular and molecular basis of atherosclerotic plaque development has a systemic inflammatory component involving primarily monocytes/macrophages and CD4 ϩ T cells. 2,3 Oxidized lipids initiate the process with subsequent responses by endothelial, vascular smooth muscle cells, and circulating cells. Peripheral-blood studies have identified gene expression signatures that are correlated with the presence of systemic inflammatory and immune-mediated disorders, as well as cardiovascular diseases, 4 suggesting that such an approach might be useful for CAD. However, although investigators have identified profiles for atherosclerosis directly from arterial wall samples in murine models and human atheroma samples, 5-9 it is unclear whether such localized processes are detectable or their severity reflected in the peripheral circulation. As a first step, we sought to identify genes for which expression levels distinguished patients with and without significant coronary artery stenosis. We approached this problem by microarray analysis on an angiographically defined patient cohort to identify a set of discriminatory genes. We then replicated these results using real-time polymerase chain reaction (RT-PCR) on 2 addi-

White Blood Cell Transcriptome Correlates With Renal Function in Acute Heart Failure

“…According to Horwitz, et al 50) expression profiles of blood cells may be a more sensitive screening test for cardiac allograft rejection than endomyocardial biopsy. Peripheral blood gene expression is also correlated with the extent of coronary heart disease 51) and chronic heart failure, 52) and could be used to differentiate patients with ischemic end-stage heart failure from patients with asymptomatic heart dysfunction. 11) Recently, Devaux, et al 53) identified a set of 3 potential biomarkers (VEGFB, THBS1 and PGF) of left ventricular dysfunction in blood cells from patients after MI.…”

Prediction of Ischemic Events on the Basis of Transcriptomic and Genomic Profiling in Patients Undergoing Carotid Endarterectomy

“…The method may be developed to identify subjects at very high risk of ischemic events. Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00479 tients, healthy controls and patients with thoracic aortic aneurysm, as well as patients differing in their extent of coronary artery disease (6)(7)(8)(9)(10). Other studies have examined diseased tissue biopsied from the site of disease, with a similar aim of identifying disease-specific gene expression (11)(12)(13)(14)(15).…”

Utility of a Genomic-based, Personalized Medicine Test in Patients Presenting With Symptoms Suggesting Coronary Artery Disease

“…These last 2 findings are consistent with the confirmed ability of the GES to identify not only the likelihood of obstructive CAD but also the burden of the disease. 36 Fourth, while clinical outcomes were monitored for at least 30 days, it may be possible that adverse cardiac events occurred after this follow-up period. Previous evaluation of patients from the COMPASS and PREDICT validity studies have shown a very low rate of major adverse cardiovascular events over 6 and 12 months followup, respectively, among patients with low GES.…”